Increased Immune Infiltration and Improved Prognosis of Head and Neck Squamous Cell Carcinoma Associated with Reduced Ancient Ubiquitous Protein 1 Gene Expression
-
Published:2024-06-12
Issue:
Volume:
Page:
-
ISSN:1073-6085
-
Container-title:Molecular Biotechnology
-
language:en
-
Short-container-title:Mol Biotechnol
Author:
Wang YiORCID, Wu Qian, Wei Xiao, Huang Gang, Feng Guangyong, Xu Hui, Gou Xiaoxia
Funder
The Guizhou Anti-Cancer Association Science and Technology Plan Project Natural Science Research Project of Guizhou Province the Natural Science Foundation of Guizhou Province The Zunyi Medical University Graduate Student Research Fund
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Caudell, J. J., Gillison, M. L., Maghami, E., Spencer, S., Pfister, D. G., Adkins, D., Birkeland, A. C., Brizel, D. M., Busse, P. M., Cmelak, A. J., Colevas, A. D., Eisele, D. W., Galloway, T., Geiger, J. L., Haddad, R. I., Hicks, W. L., Hitchcock, Y. J., Jimeno, A., Leizman, D., … Darlow, S. D. (2022). NCCN guidelines® insights: head and neck cancers, version 1.2022. Journal of the National Comprehensive Cancer Network, 20, 224–234. 2. Gu, Z., Yao, Y., Yang, G., Zhu, G., Tian, Z., Wang, R., Wu, Q., Wang, Y., Wu, Y., Chen, L., Wang, C., Gao, J., Kang, X., Zhang, J., Wang, L., Duan, S., Zhao, Z., Zhang, Z., & Sun, S. (2022). Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abo5987 3. Chi, H., Xie, X., Yan, Y., Peng, G., Strohmer, D. F., Lai, G., Zhao, S., Xia, Z., & Tian, G. (2022). Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC. Frontiers In Immunology, 13, 1018685. 4. Liu, G.-Y., Li, W.-Z., Wang, D.-S., Liang, H., Lv, X., Ye, Y.-F., Zhao, C., Ke, L.-R., Lv, S.-H., Lu, N., Bei, W.-X., Cai, Z.-C., Chen, X., Liang, C.-X., Guo, X., Xia, W.-X., & Xiang, Y.-Q. (2022). Effect of capecitabine maintenance therapy plus best supportive care vs best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy: A phase 3 randomized clinical trial. JAMA Oncology, 8, 553–561. 5. Peng, Z., Wang, Y., Fan, R., Gao, K., Xie, S., Wang, F., Zhang, J., Zhang, H., He, Y., Xie, Z., & Jiang, W. (2022). Treatment of recurrent nasopharyngeal carcinoma: A sequential challenge. Cancers (Basel), 14(17), 4111.
|
|